Last updated on June 2020

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)


Brief description of study

This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered intravenously at 2.5 milligram (mg)/kilogram (kg) on Day 1 (D1) of an every 3 weeks (Q3W) schedule. Pomalidomide will be administered orally at the approved starting dose of 4 mg daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered orally at a dose of 40 mg once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first. Approximately up to 380 participants will be randomized (320 + 60 to fulfill regional country requirements).

Clinical Study Identifier: NCT04162210

Find a site near you

Start Over

GSK Investigational Site

Albany, NY United States
  Connect »

GSK Investigational Site

Dallas, TX United States
  Connect »

GSK Investigational Site

Santa Barbara, CA United States
  Connect »

GSK Investigational Site

Pueblo, CO United States
  Connect »

GSK Investigational Site

Omaha, NE United States
  Connect »

GSK Investigational Site

Las Vegas, NV United States
  Connect »

GSK Investigational Site

Cincinnati, OH United States
  Connect »

GSK Investigational Site

Corvallis, OR United States
  Connect »

GSK Investigational Site

Eugene, OR United States
  Connect »

GSK Investigational Site

Tyler, TX United States
  Connect »

GSK Investigational Site

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.